Skip to content Skip to sidebar Skip to footer
Subscribe Now
PharmShots Interview In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis
VIEWPOINTS

PharmShots Interview: In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis

Shots: Monica spoke about the data from the NOVA P-IIIb study evaluating the efficacy of its lead candidate in Multiple Sclerosis(MS) Monica also talked about the clinical trial results and formulation of the advanced product in MS The interview gives a view of Biogen’s developing molecules in the pipeline for MS Smriti: Can you share with…
July 5, 20220Comments

Read more

PharmaShots Interview In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility
VIEWPOINTS

PharmaShots Interview: In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility

Shots: Brian spoke about opening of its new liquid biopsy lab in Phoenix, AZ and an investment of $45M for the development of its facilities Brian also talked about the establishment of lab will enhance company’s molecular profiling capabilities and launch of a blood-based diagnostic assay The interview gives a view of how Caris Life…
July 4, 20220Comments

Read more

PharmaShots' Key Highlights of Second Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2022

The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fraction Starting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 20220Comments

Read more

PharmaShots Interview In Conversation with ViiV Healthcare's Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV
VIEWPOINTS

PharmaShots Interview: In Conversation with ViiV Healthcare’s Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV

Shots: Kimberly talked about the approval for label update of ViiV’s lead candidate in HIV, and how an optional oral lead-in will be efficient for people receiving it Kimberly also spoke about ViiV’s collaboration with Janssen for the commercialization of the product  The interview gives an understanding of the different treatment options for HIV and…
June 29, 20220Comments

Read more

PharmaShots Interview In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022
VIEWPOINTS

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022

Shots Mai-Britt talked about the P-I/II clinical trial data and study design of its lead candidate in metastatic melanoma in an e-poster presentation at AACR 2022 She also spoke about IO Biotech’s unique platform with tumor defense mechanisms to kill cancer cells The interview gives a profound understanding of how IO Biotech is advancing to…
June 28, 20220Comments

Read more

PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
VIEWPOINTS

PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference

Shots: The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD Conference The spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD  The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
June 27, 20220Comments

Read more

PharmaShots Interview In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
VIEWPOINTS

PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting

Shots: Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonist Richard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumab The interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumors Smriti: Explain the details (MOA, ROA, formulations, etc.)…
June 22, 20220Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]